65 results about "Heart Muscle Cell" patented technology

Embodiments of the invention include additional methods and compositions for fabricating organoids. A unique approach has been developed for the rapid aggregation of defined number of cells using a micropillar-based template to limit the size of organoids, which are then more commonly referred to as spheroids. This procedure can be utilized to create in vitro cardiac tissue models (e.g., cardiac organoids) simply, rapidly, and inexpensively. In certain aspects an alginate-gelatin based hydrogel premixed with cardiomyocytes is used in combination with a patterned microfluidic chip / cell culture chamber having an array of micropillars to fabricate 3D cardiac organoids.

The present invention discloses a method for enhancing cardiomyocyte production from induced pluripotent stem cells (iPSCs) by adjusting the culture medium exchange process during the transition from WNT activation to inhibition for differentiation. Instead of completely replacing the culture medium, this innovative technique involves partially changing the medium, which allows for a controlled exposure to WNT activators concurrent with the introduction of WNT inhibitors. This key modification in the protocol markedly increases the consistency and efficiency of cardiomyocyte generation, reducing variability between batches. By fine-tuning the medium exchange process, this method streamlines the creation of cardiomyocytes for use in regenerative medicine, emphasizing the critical adjustment phase within the culture conditions.

The invention discloses a pathological autophagy detection method based on a myocardial cell sensing system. The pathological autophagy detection method comprises the following steps: constructing a pathological autophagy detection platform based on the myocardial cell sensing system, performing surface modification on a microelectrode array chip, culturing a cell autophagy sensitive element and performing in-vitro pathological autophagy detection. Through primary myocardial cell culture, rapamycin action and electrophysiological signal acquisition, time domain and frequency domain characteristics of myocardial cell extracellular local field potential signals are recorded and analyzed in real time, and the autophagy degree induced by rapamycin is judged. According to the method, the signal-to-noise ratio is improved through platinum black nanoparticle modification, it is ensured that the myocardial cell growth activity meets the detection requirement, the half inhibitory concentration of rapamycin is obtained through nonlinear regression analysis, and an effective means is provided for pathological autophagy research. The autophagy state can be obtained in real time without damaging the cell structure; any antigen or fluorescent molecular marker is not needed, so that cytotoxicity is avoided, and long-time monitoring is realized.

The present disclosure provides recombinant adeno-associated virus (rAAV) virions with an engineered capsid protein identified using a high-throughput sequencing screen or rational design. In particular, the disclosure provides AAV5 virions and capsid proteins with increased transduction efficiency in cardiac cells, increased cell-type selectivity, and / or other desirable properties.

This disclosure provides compositions and methods of making cells, such as allogenic cells, engineered to evade host immune responses, particularly from T cells and natural killer cells, and populations thereof. The compositions and methods for making engineered cells include making genetic modifications that reduce or eliminate the expression of an NKG2D ligand or integrate sequences encoding HLA molecules, such as HLA-E or HLA-G. Such modifications can enhance the survival of the engineered cells within a host without impeding their ability to differentiate into functional cell types, such as cardiomyocytes.

The present disclosure provides recombinant adeno-associated virus (rAAV) virions with an engineered capsid protein. In particular, the disclosure provides AAV9 virions with engineered AAV9 capsid, AAV5 / 9 chimeric capsid or combinatory capsid that achieves increased transduction efficiency in cardiac cells, increased cell-type selectivity, and / or other desirable properties.

This invention provides a device and method for real-time monitoring of stem cell exosome therapy based on a cardiomyocyte sensing system, belonging to the field of micro-nano sensing and exosome therapy monitoring technology. The device includes a cell electrophysiological sensing element 1, an electrophysiological signal acquisition module 2, a signal amplification module 3, a signal display module 4, and a cell culture incubator 5. These components are sequentially connected via cables and data lines, forming a complete signal pathway. This device is used to detect the process of embryonic stem cell exosome therapy. Through multi-concentration comparison and continuous monitoring at multiple time points, it realizes the development and utilization of a new method for monitoring embryonic stem cell exosome therapy. The detection process is real-time, non-invasive, high-throughput, and highly sensitive; the detection method is efficient and simple, and has promising applications in clinical diagnosis and treatment.

A computational system and method for digital modeling of biochemical reactions within cardiac cells are disclosed. The system comprises processors and a computer-readable storage device with instructions to maintain biological data related to cardiac cell reactions and receive user selections via a user interface to configure a simulation. The user can select a cardiac cell class, and functions to load cellular components, generate enzyme activity, load specific enzymes, and perform enzymatic reactions. The system performs in silico experiments, predicts new biological data, and compiles this into configuration data. An enzyme activity model is generated and simulated under various conditions, including user-defined enzymatic dysregulation, to replicate and study cardiac physiology and pathology. The results, such as changes in energy metabolism parameters like glucose consumption and ATP usage, are outputted. The system provides a detailed and interactive platform for research and education in cardiac electrophysiology and disease.

The invention provides an application and a method of GSH in promoting mature differentiation of hiPSC-CMs, and the method is characterized in that in the process of directionally differentiating the hiPSC-CMs into the hiPSC-CMs, an effective dose of GSH is added into a differential medium, and the optimal concentration is 20-100 [mu] M. According to the invention, through simple and economical exogenous supplement of GSH, maturation of hiPSC-CMs is systematically promoted from multiple dimensions, including enhancement of intracellular anti-oxidation defense capability; energy metabolism is promoted to be converted from glycolysis to oxidative phosphorylation; up-regulating expression of cardiac muscle cell specific structural protein and calcium ion channel related genes; mitochondrial biological generation and functions are promoted; and the cell morphological structure is induced to develop to a mature phenotype. The method is simple and convenient to operate and high in biocompatibility, the hiPSC-CMs with mature functions can be stably obtained, and a high-quality cell source is provided for application of the hiPSC-CMs in the fields of heart disease modeling, drug cardiotoxicity screening and the like.

A drug development support device is provided with a processor. The processor acquires a first variation waveform, which is a variation waveform of an external potential of an iPS myocardial cell, which is a myocardial cell derived from a human iPS cell, and which is measured in a case where a candidate substance for a pharmaceutical product is added to the iPS myocardial cell while changing the addition amount of the first variation waveform, the first variation waveform being measured in accordance with the variation waveform of an external potential of the iPS myocardial cell, the iPS myocardial cell being the myocardial cell derived from the human iPS cell. Outputting, from the prediction model, a first prediction value for each addition amount for each ion channel obtained by a first prediction value indicating the degree of inhibition of the flow of ions present in a plurality of ion channels in the iPS myocardial cells by the degree of inhibition of the candidate substance; deriving, for each ion channel, an index value indicating a dose-reaction relationship of the candidate substance on the basis of the first predicted value for each addition amount; and presenting the estimated reference information corresponding to the index value and the estimated reference information referenced in order to estimate the mechanism of action based on the candidate substance to the user.

The present invention addresses the problem of providing a method for obtaining mature cardiomyocytes which can be used for screening in drug development and for cell transplantation, and said problem is solved by providing a mature cardiomyocyte production method including a step for performing partial reprogramming in immature cardiomyocytes.

This invention belongs to the field of biomedicine and regenerative medicine technology. It discloses a chimeric polypeptide, related biomaterials, and their application in inducing cardiomyocytes. The chimeric polypeptide is obtained through family homologous domain substitution and is selected from the following groups: (1) a MEF2 chimeric polypeptide with MEF2C protein as the backbone, wherein the N-terminal and C-terminal transcriptional activation domains are replaced by homologous regions of MEF2B and MEF2D, respectively; (2) a GATA chimeric polypeptide with GATA4 protein as the backbone, wherein the N-terminal transcriptional activation domain is replaced by homologous regions of GATA1 and GATA6. This invention also provides the nucleic acid encoding the polypeptide, the construct, and a method for efficiently inducing fibroblast reprogramming into cardiomyocytes under in vitro conditions. When the chimeric polypeptide of this invention is used alone or in combination, the induced cells exhibit calcium ion oscillations earlier and have higher maturity.

It relates to a composition for cryopreserving cardiomyocytes, which contains BLEB and / or PAB (or its physiologically acceptable salt) and a cryoprotectant. It also relates to a cardiomyocyte cryopreservation kit containing the composition, a method for cryopreserving mammalian cardiomyocytes with the aforementioned composition, and the use of the aforementioned composition in the preparation of a reagent for cryopreserving mammalian cardiomyocytes.

The present invention relates to nanovesicles isolated from Melissa officinalis plant, the compositions comprising said nanovesicles and use of such nanovesicles and compositions. In particular, the nanovesicles for use in therapy and / or medical treatment are provided, preferably for use in prevention and / or treatment of ischaemia / reperfusion damage of cells or tissue. The nanovesicles, as provided herein, are able to enhance cell viability and regulate cell (for example, cardiomyocyte cell) contractility, thus protecting cells and tissues from damage or under stress conditions.

Nucleic acid molecules comprising a first sequence encoding a cyclic nucleotide gated potassium channel or a functional fragment thereof and a second sequence encoding a chemogenetically activatable cyclic adenosine monophosphate (cAMP) generating receptor or a functional fragment thereof are provided. Expression vectors comprising the molecules, fusion proteins encoded by the molecules, cells, kits and pharmaceutical compositions are also provided. Methods of hyperpolarizing a cell, depolarizing a cardiac cell and treating a disease or condition are also provided.

An object of the present invention is to provide a matured cultured cell sheet comprising cardiomyocytes without using a specific drug and a method for producing the same. Another object of the present invention is to provide a method for evaluating a compound or drug using the cultured cell sheet and a method for evaluating the quality of the cultured cell sheet comprising cardiomyocytes. The cultured cell sheet of the present invention is a cultured cell sheet comprising cardiomyocytes, wherein the cardiomyocytes are arranged with alignment, and a degree of alignment determined according to the following formula (1) is 23% or more: degree of alignment (%)=(number of rod-shaped structures included within ±15° of mode) / (total number of rod-shaped structures)×100 (1), wherein in an image obtained by microscopy of the cultured cell sheet immunostained with an anti-α-actinin antibody, where a screen horizontal direction is regarded as 0°, a degree of alignment is a frequency of rod-shaped structures included within ±15° of the mode of angles which are measured in a longitudinal direction of the rod-shaped structures detected with an α-actinin antibody within a measurement range of 71.6 μm×71.6 μm.

To provide a simple and stable method for producing large quantities of cardiac organoids. [Solution] A method for producing cardiac organoids is provided, which includes culturing a mixture of pluripotent stem cell-derived cardiomyocytes and mesenchymal stem cells in a porous vessel.

Methods for inducing proliferation of cardiomyocytes in vitro and in vivo are disclosed.

The invention discloses an application of a neuron-derived neurotrophic factor NDNF in promotion of regenerative repair and functional reconstruction of an injured heart, particularly relates to an application of the NDNF in a medicine for treating or improving the injured heart, a recombinant vector and a medicine, and belongs to the technical field of biological medicines. The invention provides application of NDNF in promotion of regenerative repair and functional reconstruction of damaged heart. The invention proves that the medicine prepared from the NDNF can be used for treating or improving the insufficiency and inflammation of the damaged heart, and particularly has a good treatment effect on the damaged heart caused by myocardial infarction, and the treatment effect specifically comprises the effect of reducing myocardial cell apoptosis and inflammation after myocardial infarction and the effect of inhibiting myocardial cell pathological hypertrophy after myocardial infarction due to overexpression of the NDNF. In addition, overexpression of the NDNF can also promote proliferation of myocardial cells after myocardial infarction.

The invention provides application of an MAPK6 inhibitor in preparation of a medicine for treating doxorubicin cardiotoxicity, and belongs to the technical field of biological medicine. It is proved for the first time that MAPK6 and myocardial cell apoptosis caused by doxorubicin toxicity have important correlation, expression of myocardial cell apoptosis genes can be remarkably affected, then the apoptosis process is regulated and controlled, and the application prospect in the aspect of developing drugs for treating doxorubicin cardiotoxicity is achieved.

This information processing device is provided with a processor. The processor acquires second-order differential data by subjecting waveform data, which indicate the change in extracellular potentials in accordance with the pulsation of cardiomyocytes, to second-order differentiation, detects a repolarization time at an action potential of the cardiomyocytes on the basis of the second-order differential data, and presents the results of the detection.

An Agrin peptide which induces proliferation of cardiomyocytes for treating a heart disease is provided.

The invention discloses an additive for enhancing physical ability for plateau hypoxia as well as a preparation method and application of the additive, and belongs to the technical field of biological medicines. The invention relates to an auxiliary agent for enhancing physical ability due to plateau hypoxia. The auxiliary agent is formed by wrapping a flavonoid compound and a carrier, the molecular weight of a flavonoid compound in the auxiliary agent is not higher than 1500Da; the carrier in the auxiliary agent is a pharmaceutically acceptable carrier. The invention also provides a preparation method and application of the auxiliary agent. Based on a procyanidine core and a synergistic anti-oxidation carrier, the aid for enhancing physical ability due to plateau hypoxia can inhibit reduction of myocardial cell mitochondrial membrane potential caused by hypoxia and reduce physical ability loss caused by hypoxia.

The present invention relates to nucleic acid regulatory elements capable of enhancing heart- and / or muscle-targeted gene expression, in particular heart- and muscle-targeted gene expression, more particularly gene expression in cardiomyocytes, methods of using these nucleic acid regulatory elements, and uses of these elements. Expression cassettes and vectors comprising these nucleic acid regulatory elements are also disclosed. The present invention is particularly useful for applications using gene therapy, more particularly heart- and / or muscle-directed gene therapy, such as the treatment of cardiovascular diseases and disorders, muscle disorders and other diseases and disorders that may benefit from high transgene expression in heart and / or muscle cells, as well as for vaccination purposes.

The invention discloses a culture experiment table for a myocardial cell hypoxia reoxygenation experiment, and relates to the field of cell culture experiment tables. The device comprises an experiment box set and a sealing shell fixedly installed on the rear end face of the experiment box set, the experiment box set comprises a bottom box part and a top box part arranged above the bottom box part, a partition inclined plate is fixedly installed in the middle of the bottom box part, and the space in the bottom box part is divided into a first equipment area and a storage area by the partition inclined plate; a vertical partition plate is fixedly installed in the middle of the top box part and divides the space in the top box part into a refrigeration area and a second equipment area, and a moving assembly is installed in the refrigeration area. The experiment box group is designed into a structure in which the bottom box part and the top box part are matched, the experiment box group is divided into four spaces with different functions through the arrangement of the separation inclined plate and the vertical separation plate, and the motor group is installed through the first equipment area, so that the motor group can stably drive the moving assembly to rotate and work.

The invention discloses pediococcus acidilactici for improving heart rhythm, sclerotin and blood pressure as well as a product and application thereof, and relates to the technical field of microorganisms. The pediococcus acidilactici NHNK-610 disclosed by the invention is preserved in the China Center for Type Culture Collection on April 25, 2024, and the preservation number of the pediococcus acidilactici NHNK-610 is CCTCC (China Center for Type Culture Collection) NO: M 2024797. The NHNK-610 has the functions of adsorbing calcium ions, up-regulating intestinal epithelial cell calcium and vitamin D absorption and transfer related gene expression, promoting intestinal absorption and transfer of calcium ions, promoting intestinal tract conversion of 1, 25-dihydroxy vitamin D3, promoting myocardial cell repair, regulating bone metabolism related genes, promoting osteoblast repair and promoting blood vessels to generate nitric oxide.

This application discloses a serum-free cryopreservation solution for cells and its applications. The serum-free cryopreservation solution comprises: 1-2% recombinant human albumin, 5-10 μM (-)-Blebbistatin, 50-100 μM antioxidant, 5-10% permeable cryoprotectant, and a basic culture medium free of phenol red indicator. This serum-free cryopreservation solution is suitable for the cryopreservation of various cell types, particularly muscle cells, especially human induced pluripotent stem cell (iPSC) differentiated cardiomyocytes. It can significantly improve the survival rate, structural integrity, and effective preservation of the physiological functions of cardiomyocytes after resuscitation. It is applicable to basic scientific research, disease modeling, drug screening, and clinical treatment related to cardiomyocytes.